iStockSun Pharma on Wednesday said it has entered into an exclusive patent licensing agreement with Danish-drugmaker Lundbeck to market and distribute its own version of antidepressant medication Vortioxetine in India under the brand name Vortidiftm.
The territory of the licensing agreement will only cover India.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
The product is approved in over 80 countries, including the US, EU, Canada and Australia.
“Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavour to bring innovative medicines that fill a need gap," said Kirti Ganorkar, CEO of India Business, Sun Pharma.
"MDD is a serious and complicated disorder and Vortidiftm will serve as an important novel treatment option for patients in India,” Ganorkar said.
MDD is one of the leading causes of disability, affecting approximately 246 million people globally and 35 million people in India.
MDD is characterised by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behaviour.
Sun Pharma has a leadership position by prescriptions in India. With a strong product portfolio, Sun Pharma’s central nervous system (CNS) division constantly strives to provide innovative solutions to patients and health care providers in India.
The territory of the licensing agreement will only cover India.
Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults.
The product is approved in over 80 countries, including the US, EU, Canada and Australia.
“Sun Pharma is the leader in the neuro-psychiatry therapy in India and we always endeavour to bring innovative medicines that fill a need gap," said Kirti Ganorkar, CEO of India Business, Sun Pharma.
"MDD is a serious and complicated disorder and Vortidiftm will serve as an important novel treatment option for patients in India,” Ganorkar said.
MDD is one of the leading causes of disability, affecting approximately 246 million people globally and 35 million people in India.
MDD is characterised by pronounced changes in mood coupled with distinct psychological and vegetative changes, including sleep, appetite disturbance, subjective fatigue, loss of motivation and drive, ruminative feelings of guilt and despair, problems maintaining mental focus, and suicidal thinking and behaviour.
Sun Pharma has a leadership position by prescriptions in India. With a strong product portfolio, Sun Pharma’s central nervous system (CNS) division constantly strives to provide innovative solutions to patients and health care providers in India.
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
